Rabbit Polyclonal STT3A Antibody

The STT3A antibody targets the STT3A protein, a catalytic subunit of the oligosaccharyltransferase (OST) complex located in the endoplasmic reticulum (ER). The OST complex mediates N-linked glycosylation, a critical post-translational modification where oligosaccharides are attached to asparagine residues of nascent polypeptides. This process is essential for protein folding, quality control, and cellular interactions. STT3A, along with its paralog STT3B, represents one of two major OST isoforms in mammals. While STT3A primarily acts co-translationally during protein synthesis, STT3B facilitates post-translational glycosylation of skipped sites. Dysregulation of STT3A is implicated in diseases such as cancer, congenital disorders of glycosylation (CDGs), and neurodegenerative conditions. Antibodies against STT3A are widely used in research to study ER-associated glycosylation mechanisms, protein trafficking, and disease pathogenesis. They enable detection of STT3A expression levels, subcellular localization via immunofluorescence or immunohistochemistry, and functional studies through knockdown or inhibition. Commercial STT3A antibodies are typically validated in Western blotting, immunoprecipitation, and ELISA, with applications spanning cell biology, oncology, and biomarker discovery. Recent studies also explore its role in immune evasion by pathogens and therapeutic targeting of glycosylation pathways.